Multiple Sclerosis
RSSArticles
-
Multiple Sclerosis Disease Burden May Be Underestimated
Prescription drug prices, indirect productivity loss drive care costs significantly higher for these patients compared to others.
-
Multiple Sclerosis and Immune Response to COVID-19 Vaccination
A large group of patients with multiple sclerosis taking various disease-modifying therapies did not respond uniformly to COVID-19 vaccination.
-
Infections Before Age 20 Years Increase the Risk of Multiple Sclerosis
Researchers found patients diagnosed with infection in adolescence were at higher risk for multiple sclerosis, even after exclusion of infectious mononucleosis, pneumonia, and central nervous system infection.
-
Multiple Sclerosis and Vascular Disease
Researchers evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with multiple sclerosis (MS) compared to healthy controls. MS patients exhibited less systemic vascular disease and more small vessel disease in the brain vs. controls.
-
Even Moderate COVID-19 Cases Can Cause Serious Neurological Problems
Strokes, seizures, and movement disorders just a few complications observed.
-
Ibudilast Shows Promise for the Treatment of Progressive MS
A Phase II trial of ibudilast in progressive multiple sclerosis demonstrated a decreased rate of brain atrophy when compared to placebo.
-
Childhood Head Trauma and Risk of Subsequent Diagnosis of Multiple Sclerosis
A large study that reviewed longitudinally collected data from the national Swedish Patient Register found that head trauma in adolescents was associated with an increased risk of subsequent diagnosis of multiple sclerosis.
-
Exploring Cortical Pathology in Multiple Sclerosis With Routine MRI
In this MRI and histopathological study, the investigators showed that cortical T1w/T2w ratio was unrelated to myelin density, but had a strong correlation with dendritic density. Furthermore, abnormal values within the posterior cingulate cortex correlated with impairment in cognitive domains.
-
Disability in Patients with Multiple Sclerosis: A Long-Term Study
SYNOPSIS: In a long-term study, the rate of disability progression in treated relapsing and progressive, multiple sclerosis patients was lower than that reported in earlier natural history studies.
-
Disease Rebound After Stopping Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis
A review of patients with relapsing-remitting multiple sclerosis who discontinued fingolimod therapy showed that five out of 46 (10.9 %) of these patients developed a rebound phenomenon between 4 to 16 weeks, where disease activity returns and often exceeds pre-treatment levels.